Journal article
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T Flaherty, Michael Hennig, Sandra J Lee, Paolo A Ascierto, Reinhard Dummer, Alexander MM Eggermont, Axel Hauschild, Richard Kefford, John M Kirkwood, Georgina V Long, Paul Lorigan, Andreas Mackensen, Grant McArthur, Steven O'Day, Poulam M Patel, Caroline Robert, Dirk Schadendorf
LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2014
Abstract
BACKGROUND: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials. METHODS: We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR). We correlated HRs for overall survival and PFS, weighted by sample size or by precision of the HR estimate, assuming fixed and random effects. We did sensitivity analyses according to presence of cro..
View full abstractGrants
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
DS has received research funding from Merck, and has had consultancies or participated in advisory boards with GlaxoSmithKline, Roche, Bristol Myers-Squibb, Merck, Amgen, Delcath, and Novartis. KTF has had consultancies with Roche, GlaxoSmithKline, Celgene, and Novartis. GVL is consultant advisor to GlaxoSmithKline, Roche, Novartis, Bristol Myers-Squibb, and Amgen, and has received honoraria from GlaxoSmithKline and Roche. AM has participated in advisory boards with GlaxoSmithKline, Roche, and Bristol Myers-Squibb. PAA has received research funding from Bristol Myers-Squibb, and has had consultancies or participated in advisory boards for Bristol Myers-Squibb, Roche-Genentech, GlaxoSmithKline, and Novartis. PMP has had consultancies or participated in advisory boards with GlaxoSmithKline, Roche, Bristol Myers-Squibb, and Schering Plough Merck. CR is consultant for GlaxoSmithKline, Roche, Novartis, Bristol Myers-Squibb, Merck, Amgen, and Bayer. AH is consultant advisor and received honoraria from Roche, Genentech, Amgen, GlaxoSmithKline, Bristol Myers Squibb, Merck/MSD, Pfizer, and Novartis. RK has received institutional reimbursement for advisory board participation from GlaxoSmithKline, Novartis, Roche, BMS, and Sanofi-Aventis and institutional reimbursement-honoraria for educational symposia from Merck. SO'D has received research support from Merck, Roche, BMS, and Novartis and served on the speakers bureau of Merck and BMS. MH is an employee at GlaxoSmithKline in Germany. PL has had consultancies or participated in advisory boards of BMS, Roche, GlaxoSmithKline, Novartis, and Celgene. GM has had consultancies or participated in advisory boards with GlaxoSmithKline, Roche, Bristol Myers-Squibb, and Schering Plough/Merck. AMME received honorary fees for advisory board participation for Amgen, BMS, GlaxoSmithKline, MedImmune, and Merck. JMK has received honorary fees for advisory board participation for BMS, GlaxoSmithKline, Celgene, Vical, and Merck. All other authors declare that they have no conflicts of interest.